Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis.
Journal: Open forum infectious diseases
Published: May 22, 2026
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
Journal: Circulation. Heart failure
Published: December 29, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVE.
Journal: Journal of the American Heart Association
Published: December 11, 2025
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.
Journal: The lancet. HIV
Published: December 05, 2025
Pain is associated with reduced adherence to safer injection practices among people who inject opioids.
Journal: Harm reduction journal
Published: December 05, 2025
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: November 06, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.
Journal: AIDS (London, England)
Published: August 26, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.
Journal: AIDS (London, England)
Published: August 26, 2025
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.
Journal: The lancet. HIV
Published: July 01, 2025
No evidence of pitavastatin effect on muscle area or density among people with HIV.
Journal: AIDS (London, England)
Published: May 30, 2025
Last Updated: 09/26/2026